Comparison

Biosimilar vs Red Book Peds ID Chart

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

Biosimilar

This app serves as a reference for biosimilar and interchangeable biologic drugs, drawing from the FDA's Purple Book. It offers essential prescribing and dispensing information for healthcare professionals managing complex drug therapeutics.

Highlights
  • FDA Purple Book reference
  • Prescribing information
  • Dispensing guidance
  • Biologic drug data
  • Interchangeable product details
Features
Read full description

Biologic drugs offer important treatment options for patients suffering from auto-immune disorders such as rheumatoid arthritis and for common cancers including breast and colon. Biosimilar and interchangeable products, which can loosely be thought of as ‘generic’ biologics, are important for promoting competition and driving down costs. The FDA maintains a list of approved biosimilars in the Purple Book. The Biosimilar iOS app provides a handy reference to the Purple Book as well as important information related to prescribing and dispensing for clinicians and pharmacists navigating this complex area of drug therapeutics. ** Disclaimer ** - non-medical users should ask for a doctor’s advice in addition to using this app and before making any medical decisions.

About

Red Book Peds ID Chart

Features
Read full description

"Try before you buy" - Download the FREE App, which includes sample content. An in-App purchase is required to unlock all content.   The fully revised Red Book Pediatric Infectious Diseases Clinical Decision Support Chart, 3rd edition chart distills essential tables and algorithms from the Red Book, 33rd Edition into a colorful, enlarged, easy-to-navigate format. Designed for quick clinical reference, it includes new, exclusive tables synthesizing key guidance on immunizations, antibiotic prophylaxis, immune globulin, and major pediatric infections—such as staphylococcal and streptococcal disease, COVID-19/MIS-C, tuberculosis, Lyme disease, HIV, and care of immunocompromised children and adolescents. Fully revised and updated, the third edition of this full-color chart collects many of the most clinically useful tables, algorithms, and other items from the Red Book, 33rd Edition and presents them in an enlarged, enhanced colorized format that is lightweight, portable, and easy to navigate. Additionally, new tables have been created exclusively for this chart, synthesizing important clinical information from the Red Book text. Topics include: - Staphylococcal Infections - Streptococcal Infections - COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) - Diarrheal Infections - Immunizations - Antibiotic Prophylaxis - Immune Globulin - Kawasaki Disease - Tuberculosis - Lyme Disease - Varicella-Zoster - Fungal Infections - Genital and Neonatal Herpes - Syphilis - HIV - Immunocompromised Children and Adolescents Content licensed from printed ISBN 10: 1610027426 & ISBN 13: 9781610027427   If you have any questions or comments, email us any time: customersupport@skyscape.com or call 508-299-30000   Privacy Policy-https://www.skyscape.com/terms-of-service/privacypolicy.aspx Terms and Conditions-https://www.skyscape.com/terms-of-service/licenseagreement.aspx   Editor(s): David W. Kimberlin, MD, FAAP Publisher: American Academy of Pediatrics

Screenshots

Biosimilar4 screens
Red Book Peds ID Chart4 screens

Verdict

The call

The clearest difference is price: Red Book Peds ID Chart at Free against Biosimilar's $1.99. Red Book Peds ID Chart also leads on iOS requirement (13.0 vs 17.6). Biosimilar's advantage is in-app purchases (none vs 1) and ads (none vs shown). On device support there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Red Book Peds ID Chart is free to download; Biosimilar costs $1.99 up front. Red Book Peds ID Chart sells 1 one-off in-app purchase. Biosimilar asks for nothing beyond the download.

Scorecard4 real differences · 5 level
Biosimilar versus Red Book Peds ID Chart: the parameters behind the verdict, then further details
ParameterBiosimilarRed Book Peds ID Chart
Price$1.99Free — better
Rating5.0 (2 ratings) — better—
Number of ratings2 — better—
Update frequencyEvery 3 months—
AdsNo — betterYes
In-app purchasesNo — betterYes
MonetizationPaid—
DevicesiPhone, iPadiPhone, iPad, iPod — better
Requires iOS17.613.0 — better
Further details — not scored
Size2 MB150 MB
Age rating17+17+
DeveloperDabbling Badger LLCSkyscape Medpresso Inc

In-app purchases

None

Biosimilar

No in-app purchases

1 purchases

Red Book Peds ID Chart

One-time1
  • Red Book Pediatric Infect. Diseases$49.95

Questions

Is Biosimilar free?
Biosimilar costs $1.99, with no in-app purchases.
Is Red Book Peds ID Chart free?
Red Book Peds ID Chart is free to download, with in-app purchases available.
Do Biosimilar or Red Book Peds ID Chart have ads?
Red Book Peds ID Chart shows ads; Biosimilar does not.

Other comparisons